-+ 0.00%
-+ 0.00%
-+ 0.00%

Matchpoint Therapeutics closes $150 million Series B with T1D Fund participation

PUBT·10/07/2026 21:22:11
Listen to the news
Matchpoint Therapeutics closes $150 million Series B with T1D Fund participation
  • Matchpoint Therapeutics raised USD 150 million in a Series B round co-led by Nextech Invest, Norwest.
  • T1D Fund A Breakthrough T1D Venture LLC participated alongside other new and existing investors.
  • Matchpoint develops precision covalent oral small-molecule drugs for autoimmune, inflammatory diseases.
  • Funding to advance lead program MPT-062, an oral first-in-class T cell modulator, toward clinical proof-of-concept.
  • Company expects MPT-062 to enter clinical development in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. T1D Fund A Breakthrough T1D Venture LLC published the original content used to generate this news brief on October 07, 2026, and is solely responsible for the information contained therein.